To assess the safety, efficacy, and patient satisfaction of a newly described technique for the treatment of mild to moderate lash ptosis performed as augmentation to upper eyelid blepharoplasty.
Patient medical records for 27 consecutive cases of upper eyelid blepharoplasty between January 2016 and June 2017 and 19 consecutive cases of upper eyelid blepharoplasty with the laser lash tilt procedure between July 2016 and January 2017 performed by the senior author were retrospectively reviewed. Lash position in preoperative and postoperative photographs was graded in a randomized masked fashion on a 4-point scale by 5 oculoplastic surgeons.
There was a significant improvement in mean lash position scores for the control group (0.52 ± 0.34, p < 0.001) with mean lash score improving from 1.14 ± 0.46 before surgery to 0.62 ± 0.46 after blepharoplasty alone. There was also significant improvement in mean lash position scores for the laser lash group (0.98 ± 0.52, p < 0.01) with mean lash score improving from 1.66 ± 0.62 before surgery to 0.68 ± 0.50 after blepharoplasty with laser lash treatment. The improvement in lash position seen in the laser lash group was significantly greater than the improvement seen in the control group (p = 0.001). There were no complications and all patients were satisfied with their results.
Compared with upper eyelid blepharoplasty alone, the addition of the CO2 laser lash tilt technique provides a significant improvement in the upward tilt of the eyelashes as they emerge from the eyelid margin.
CO2 laser lash rotation enhancement, when performed in conjunction with upper eyelid blepharoplasty, is a safe and effective technique for improving mild to moderate lash ptosis with excellent patient satisfaction.
*Duke University Medical Center, Department of Ophthalmology, Durham, North Carolina, U.S.A.
†Duke University Medical Center, Department of Ophthalmology and Department of Biostatistics, Durham, North Carolina, U.S.A.
‡Duke University Medical Center, Department of Ophthalmology and Department of Dermatology, Durham, North Carolina, U.S.A.
Accepted for publication February 12, 2019.
Presented at the ASOPRS 2017 Fall Scientific Symposium on November 10, 2017 in Chicago, IL.
Dr. Julie Woodward serves as a consultant and is on the speaker’s bureau for Allergan, Galderma, Merz Aesthetic, Lutronic, and SkinCeuticals/L’Oréal. There are no conflicts for the other authors.
Address correspondence and reprint requests to Nicole Langelier, M.D., Virginia Eye Institute, 12018 W Broad Street, Suite #102, Henrico, VA 23233. E-mail: email@example.com